News
Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...
GlobalData on MSN1d
Nektar’s stock doubles on eczema therapy success in Phase IIb studyNektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin ...
Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...
Nektar Therapeutics (NASDAQ:NKTR) announced Tuesday that its lead asset, rezpegaldesleukin, reached the main goal in a ...
Zacks Investment Research on MSN2h
NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis StudyNektar Therapeutics NKTR announced that the phase IIb REZOLVE-AD study evaluating its lead pipeline candidate, ...
The agency said it will evaluate whether further regulatory action is needed after investigating the deaths of two patients ...
Nektar Therapeutics is enjoying the sweet taste of clinical trial success after years of swallowing bitter pills. | Nektar Therapeutics is enjoying the sweet taste of clinical trial success after ...
A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...
The Food and Drug Administration in February granted fast track designation for rezpegaldesleukin to treat adults and pediatric patients 12 years and up with moderate to severe atopic dermatitis, the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback